In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

Orna Therapeutics (through its wholly owned subsidiary ReNAgade Therapeutics Inc.) announced a three-year strategic research collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq ...

Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price ...

In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research ...

Cardiol Therapeutics President and CEO, David ElsleyNEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView announces the release of an informative interview with Cardiol Therapeutics ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other biotech stocks with the biggest upside potential. Improving Trends for Biotech ...

Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it has closed its previously announced registered direct ...

On Friday, Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin. Emi-Le was generally well tolerated ...

BioXcel Therapeutics (BTAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE ...

Mizuho Securities analyst Uy Ear has maintained their neutral stance on RVNC stock, giving a Hold rating on January 17. Uy Ear has given his Hold rating due to a combination of factors surrounding ...